Mitochondrial cytopathy in adults: what we know so far.

  title={Mitochondrial cytopathy in adults: what we know so far.},
  author={Bruce H Cohen and Deborah Rukin Gold},
  journal={Cleveland Clinic journal of medicine},
  volume={68 7},
          625-6, 629-42
  • B. Cohen, D. R. Gold
  • Published 1 July 2001
  • Medicine, Biology
  • Cleveland Clinic journal of medicine
Mitochondrial cytopathies are a diverse group of inherited and acquired disorders that result in inadequate energy production. They can be caused by inheritable genetic mutations, acquired somatic mutations, exposure to toxins (including some prescription medications), and the aging process itself. In addition, a number of well-described diseases can decrease mitochondrial energy production; these include hyperthyroidism, hypothyroidism, and hyperlipidemia. 

Figures from this paper

Mitochondrial diseases: a review Doenças mitocondriais: uma revisão

Gene therapy emerges as potential therapeutic strategy for more efficient treatment of mitochondrial diseases, as a combined analysis of clinical data, biochemical, morphological and laboratory tests must be performed to evaluate mitochondrial respiratory chain activity and integrity of nuclear and mitochondrial genomes.

Underlying role of mitochondrial mutagenesis in the pathogenesis of a disease and current approaches for translational research

It is suggested that environmental agents can cause damage in mitochondrial DNA and consequently lead to mutagenesis and current approaches for handling mitochondrial diseases, as well as available prenatal diagnostic tests, towards eliminating these maternally inherited diseases.

Neuropsychologic Profile of a High-functioning Family With a Mitochondrial Cytopathy

The neuropsychologic profile of 3 family members diagnosed with the same mitochondrial cytopathy corresponding to a defect in the respiratory chain was examined, finding general trends were reflective of executive function impairment associated with dysfunction of frontal-subcortical systems.

Medication-induced mitochondrial damage and disease.

Since the first mitochondrial dysfunction was described in the 1960s, the medicine has advanced in its understanding the role mitochondria play in health and disease. Damage to mitochondria is now

Role of Mitochondria in Epilepsy

The dramatic clinical presentation of many seizure disorders has been recognized for millennia and of particular interest has been a group of neuromuscular disorders genetically linked to the mitochondrial genome.

Toxic myopathy with multiple deletions in mitochondrial DNA associated with long‐term use of oral anti‐viral drugs for hepatitis B: A case study

  • T. FujiiK. Takase J. Kira
  • Biology, Medicine
    Neuropathology : official journal of the Japanese Society of Neuropathology
  • 2019
It is indicated that long‐term oral antiviral therapy for hepatitis B can induce chronic oxidative damage to mtDNA resulting in qualitative mtDNA abnormalities and toxic myopathy.

Sigmoid volvulus in a patient with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS): a rare occurrence

The authors report a case detailing a 56-year-old woman's final hospitalisation from the gastrointestinal sequelae of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) (Co Q10 deficiency variant).

Mitochondrial dysfunction and molecular pathways of disease.




Oxidative Phosphorylation Diseases

The mitochondrial cytopathies are a heterogeneous group of diseases associated with defects in mitochondrial ATP production that affect the brain, skeletal muscle, heart, kidney, and liver.

Mitochondrial myopathy diagnosis.

Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: A distinctive clinical syndrome

It is believed that MELAS represents a distinctive syndrome and that it can be differentiated from two other clinical disorders that also are associated with mitochondrial myopathy and cerebral disease: Kearns‐Sayre syndrome and the myoclonus epilepsy ragged red fiber syndrome.

Mitochondrial diseases in man and mouse.

The essential role of mitochondrial oxidative phosphorylation in cellular energy production, the generation of reactive oxygen species, and the initiation of apoptosis has suggested a number of novel mechanisms for mitochondrial pathology.

Respiratory chain encephalomyopathies: a diagnostic classification.

A system is developed that allows classification of the diagnosis of RC encephalomyopathy in possible, probable and definite categories of certainty, which will be of value to the clinician.

Mitochondrial deafness.

The spectrum of different mitochondrial mutations associated with hearing impairment suggests that the pathogenic process involves the accumulation of abnormal translation products inside mitochondria, in sensitive cells of the auditory system, which leads to a prediction of the involvement of a novel class of nuclear genes in hearing impairment, namely those with roles in 'mitochondrial protein quality control'.

Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder.

Examination of 12 MNGIE probands revealed homozygous or compound-heterozygous mutations in the gene specifying thymidine phosphorylase (TP), indicating that loss-of-function mutations in TP cause the disease.

A mutation in the tRNALeu(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies

An A-to-G transition mutation at nucleotide pair 3,243 in the dihydrouridine loop of mitochondrial tRNALeu(UUR) that is specific to patients with MELAS is reported, which creates an Apal restriction site and could perform a simple molecular diagnostic test for the disease.

Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy.

This finding demonstrated that a nucleotide change in a mitochondrial DNA energy production gene can result in a neurological disease.